{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:13:51Z","timestamp":1760148831499,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Introduction: Antimicrobial resistance is a major healthcare issue responsible for a large number of deaths. Many reviews identified that PKPD data are in favor of the use of continuous infusion, and we wanted to review clinical data results in order to optimize our clinical practice. Methodology: We reviewed Medline for existing literature comparing continuous or extended infusion to intermittent infusion of betalactams. Results: In clinical studies, continuous infusion is as good as intermittent infusion. In the subset group of critically ill patients or those with an infection due to an organism with high MIC, a continuous infusion was associated with better clinical response. Conclusions: Clinical data appear to confirm those of PK\/PD to use a continuous infusion in severely ill patients or those infected by an organism with an elevated MIC, as it is associated with higher survival rates. In other cases, it may allow for a decrease in antibiotic daily dosage, thereby contributing to a decrease in overall costs.<\/jats:p>","DOI":"10.3390\/antibiotics12061052","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T02:28:56Z","timestamp":1686796136000},"page":"1052","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimizing Betalactam Clinical Response by Using a Continuous Infusion: A Comprehensive Review"],"prefix":"10.3390","volume":"12","author":[{"given":"Sylvain","family":"Diamantis","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Groupe Hospitalier Sud Ile de France, 77000 Melun, France"},{"name":"DYNAMIC Research Unit, Universit\u00e9 Paris-Est-Creteil, 94320 Thiais, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Chakvetadze","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Groupe Hospitalier Sud Ile de France, 77000 Melun, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"de Pontfarcy","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Groupe Hospitalier Sud Ile de France, 77000 Melun, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9609-8246","authenticated-orcid":false,"given":"Matta","family":"Matta","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Groupe Hospitalier Sud Ile de France, 77000 Melun, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s00134-017-4878-x","article-title":"Antimicrobial resistance in the next 30 years, hu-mankind, bugs and drugs: A visionary approach","volume":"43","author":"Bassetti","year":"2017","journal-title":"Intensiv. Care Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: A retrospective cohort study","volume":"18","author":"Zilberberg","year":"2014","journal-title":"Crit. Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1469-0691.2001.00065.x","article-title":"Evaluating and Predicting the Ecologic Impact of Antibiotics","volume":"7 suppl 5","author":"Andremont","year":"2001","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1345\/aph.1L638","article-title":"Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria","volume":"43","author":"Moriyama","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/QCO.0000000000000755","article-title":"Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections","volume":"34","author":"Gatti","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-Lactam s and \u03b2-Lactamase Inhibitors: An Overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"De Rosa, M., Verdino, A., Soriente, A., and Marabotti, A. (2021). The Odd Couple(s): An Overview of Beta-Lactam Antibiotics Bearing More than One Pharmacophoric Group. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020617"},{"key":"ref_8","first-page":"251","article-title":"Production of beta-lactam antibiotics and its regulation","volume":"15","author":"Demain","year":"1991","journal-title":"Proc. Natl. Sci. Counc. Repub. China Part B Life Sci."},{"key":"ref_9","first-page":"226","article-title":"On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae","volume":"10","author":"Fleming","year":"1929","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/bj0790377","article-title":"The structure of cephalosporin C","volume":"79","author":"Abraham","year":"1961","journal-title":"Biochem. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(85)90097-X","article-title":"Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem\/cilastatin","volume":"78","author":"Birnbaum","year":"1985","journal-title":"Am J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/0002-9343(85)90196-2","article-title":"Aztreonam: The first monobactam","volume":"78","author":"Sykes","year":"1985","journal-title":"Am J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper","volume":"46","author":"Alffenaar","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","article-title":"Continuous versus Intermittent \u03b2-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials","volume":"194","author":"Roberts","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.ajic.2006.05.227","article-title":"Pharmacodynamics: Relation to antimicrobial resistance","volume":"34","author":"Rybak","year":"2006","journal-title":"Am. J. Infect. Control."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Maguigan, K.L., Al-Shaer, M.H., and Peloquin, C.A. (2021). Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK\/PD Approach. Antibiotics, 10.","DOI":"10.3390\/antibiotics10101154"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1128\/AAC.01232-08","article-title":"Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus","volume":"53","author":"Hughes","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijantimicag.2006.02.020","article-title":"Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients","volume":"28","author":"Rafati","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6 g daily) in critically ill patients: Continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","first-page":"283","article-title":"piperacillin\/tazobactam in continuous infusion versus intermittent infusion in children with febrile neutropenia","volume":"71","year":"2019","journal-title":"Rev. Investig. Clin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11096-015-0208-y","article-title":"Continuous versus intermittent piperacillin\/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa","volume":"38","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1592\/phco.22.7.471.33665","article-title":"Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital","volume":"22","author":"Grant","year":"2002","journal-title":"Pharmacotherapy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1128\/AAC.00329-06","article-title":"Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection","volume":"50","author":"Lau","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","article-title":"BLING II Investigators for the ANZICS Clinical Trials Group. A Multicenter Randomized Trial of Continuous versus Intermittent \u03b2-Lactam Infusion in Severe Sepsis","volume":"192","author":"Dulhunty","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2004.08.012","article-title":"Pharmacokinetics of piperacillin-tazobactam: Intermittent dosing versus continuous infusion","volume":"25","author":"Buck","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2146\/ajhp050323","article-title":"Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection","volume":"63","author":"DeRyke","year":"2006","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijantimicag.2008.10.025","article-title":"Clinical cure of ventilator-associated pneumonia treated with piperacillin\/tazobactam administered by continuous or intermittent infusion","volume":"33","author":"Lorente","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hyun, D.G., Seo, J., Lee, S.Y., Ahn, J.H., Hong, S.B., Lim, C.M., Koh, Y., and Huh, J.W. (2022). Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study. Antibiotics, 11.","DOI":"10.3390\/antibiotics11111508"},{"key":"ref_30","first-page":"2949","article-title":"Clinical efficacy of continuous infusion of piperacillin\/tazobactam in severe pneumonia patients: A randomized controlled clinical trial","volume":"3","author":"Li","year":"2010","journal-title":"Mod. Prev. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jac\/dkv288","article-title":"DALI Study Group. Is prolonged infusion of piperacillin\/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic\/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort","volume":"71","author":"Lipman","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-Lactam Infusion in Severe Sepsis (BLISS): A prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Sulaiman","year":"2016","journal-title":"Intensive Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: A multicenter double-blind, randomized controlled trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jac\/dkl478","article-title":"Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study","volume":"59","author":"Roberts","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1592\/phco.21.6.549.34539","article-title":"Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia","volume":"21","author":"McNabb","year":"2001","journal-title":"Pharmacotherapy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0924-8579(01)00329-6","article-title":"Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia","volume":"17","author":"Nicolau","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9610(00)00388-3","article-title":"Intermittent and continuous ceftazidime infusion for critically ill trauma patients","volume":"179","author":"Hanes","year":"2000","journal-title":"Am. J. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.clinthera.2007.11.003","article-title":"Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: A retrospective, nonrandomized, open-label, historical chart review","volume":"29","author":"Lorente","year":"2007","journal-title":"Clin. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/PL00008370","article-title":"Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children","volume":"159","author":"Rappaz","year":"2000","journal-title":"Eur. J. Pediatr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1128\/AAC.00174-09","article-title":"Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis","volume":"53","author":"Hubert","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s15010-009-8116-5","article-title":"Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis","volume":"37","author":"Riethmueller","year":"2009","journal-title":"Infection"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijantimicag.2013.08.019","article-title":"Continuous versus intermittent infusion of cefepime in neurosurgical patients with post-operative intracranial infections","volume":"43","author":"Huang","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5414\/CPP43360","article-title":"Cefepime in critically ill patients: Continuous infusion vs. an intermittent dosing regimen","volume":"43","author":"Georges","year":"2005","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkl053","article-title":"Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis","volume":"57","author":"Han","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1128\/AAC.01318-06","article-title":"Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial","volume":"51","author":"Sakka","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","first-page":"553","article-title":"Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly","volume":"47","author":"Okimoto","year":"2009","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1345\/aph.1G467","article-title":"Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli","volume":"40","author":"Lorente","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4103\/0366-6999.205859","article-title":"Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study","volume":"130","author":"Zhao","year":"2017","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1186\/cc11405","article-title":"Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: A randomized open-label controlled trial","volume":"16","author":"Chytra","year":"2012","journal-title":"Crit. Care"},{"key":"ref_50","first-page":"44","article-title":"Continuous versus intermittent intravenous meropenem in severe sepsis","volume":"5","author":"Helmy","year":"2015","journal-title":"IJPBS"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/ajhp\/60.22.2321","article-title":"Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: A time-motion study","volume":"60","author":"Florea","year":"2003","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.iccn.2004.07.011","article-title":"The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion","volume":"21","author":"Kotapati","year":"2005","journal-title":"Intensive Crit. Care Nurs."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1592\/phco.19.8.620.31525","article-title":"A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis","volume":"19","author":"Bosso","year":"1999","journal-title":"Pharmacotherapy"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1128\/AAC.00867-13","article-title":"Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa","volume":"57","author":"Felton","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jcrc.2018.07.003","article-title":"Emergence of antimicrobial resistance to piperacillin\/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study","volume":"47","author":"Dhaese","year":"2018","journal-title":"J. Crit. Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e4599","DOI":"10.1093\/cid\/ciaa1306","article-title":"Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance","volume":"73","author":"Tamma","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Gatti, M., Cojutti, P.G., Pascale, R., Tonetti, T., Laici, C., Dell\u2019Olio, A., Siniscalchi, A., Giannella, M., Viale, P., and Pea, F. (2021). Assessment of a PK\/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and\/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections. Antibiotics, 10.","DOI":"10.3390\/antibiotics10111311"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s10096-021-04294-3","article-title":"The MOBILISE study: Utilisation of ambulatory pumps in the inpatient setting to administer continuous antibiotic infusions-A randomised controlled trial","volume":"40","author":"McCarthy","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.medmal.2020.10.019","article-title":"Home intravenous antibiotherapy and the proper use of elastomeric pumps: Systematic review of the literature and proposals for improved use","volume":"51","author":"Diamantis","year":"2021","journal-title":"Infect. Dis. Now"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15593258211059325","DOI":"10.1177\/15593258211059325","article-title":"Influence of Concentration and Temperature on Stability of Imipenem Focused on Solutions for Extended Infusion","volume":"19","author":"Sornsuvit","year":"2021","journal-title":"Dose Response"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/6\/1052\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:55:20Z","timestamp":1760126120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/6\/1052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":60,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["antibiotics12061052"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12061052","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}